Indivior PLC (INDV) Receives Average Rating of “Buy” from Brokerages
Shares of Indivior PLC (LON:INDV) have earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the firm. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is GBX 419.29 ($5.41).
INDV has been the topic of several recent research reports. Deutsche Bank AG restated a “buy” rating and set a GBX 395 ($5.10) price target on shares of Indivior PLC in a research report on Friday, February 3rd. Numis Securities Ltd restated a “buy” rating and set a GBX 450 ($5.81) price target on shares of Indivior PLC in a research report on Thursday, February 16th. Citigroup Inc raised their price target on Indivior PLC from GBX 320 ($4.13) to GBX 340 ($4.39) and gave the stock a “neutral” rating in a research report on Thursday, March 2nd. Stifel Nicolaus restated a “buy” rating and set a GBX 500 ($6.45) price target on shares of Indivior PLC in a research report on Friday, February 3rd. Finally, Royal Bank of Canada lowered Indivior PLC to a “sector performer” rating and lifted their price objective for the stock from GBX 370 ($4.78) to GBX 390 ($5.03) in a research report on Monday, March 13th.
Indivior PLC (LON:INDV) traded up 0.22% on Friday, reaching GBX 323.00. The company’s stock had a trading volume of 1,758,865 shares. The firm’s market cap is GBX 2.33 billion. Indivior PLC has a 52-week low of GBX 159.00 and a 52-week high of GBX 382.30. The stock’s 50 day moving average price is GBX 325.39 and its 200 day moving average price is GBX 323.99.
In other Indivior PLC news, insider Lorna Parker acquired 1,231 shares of the business’s stock in a transaction dated Friday, February 24th. The shares were purchased at an average cost of GBX 342 ($4.41) per share, for a total transaction of £4,210.02 ($5,434.39).
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.